Status:
COMPLETED
A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients
Lead Sponsor:
Bayer
Collaborating Sponsors:
External supplier: HEVA
Conditions:
Peripheral Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
This is a study to learn more about French patients who have peripheral artery disease (PAD) and who have had a revascularization procedure. With this procedure, doctors use surgery or a thin tube (ca...
Eligibility Criteria
Inclusion
- PAD revascularized population
- Patients with hospital stays identified through ICD-10 and surgical procedure (CCAM) codes:
- Patient with a lower-extremity PAD.
- Patient with a lower limb revascularization procedure.
Exclusion
- PAD revascularized population
- None
Key Trial Info
Start Date :
March 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 7 2022
Estimated Enrollment :
227613 Patients enrolled
Trial Details
Trial ID
NCT04824729
Start Date
March 24 2021
End Date
January 7 2022
Last Update
April 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PMSI
Multiple Locations, France